Barclays’s Anterix ATEX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$82.5K Sell
2,160
-16,629
-89% -$526K ﹤0.01% 4106
2025
Q4
$410K Buy
18,789
+2,388
+15% +$49.6K ﹤0.01% 3957
2025
Q3
$352K Sell
16,401
-8,411
-34% -$189K ﹤0.01% 3998
2025
Q2
$636K Sell
24,812
-8,309
-25% -$243K ﹤0.01% 3619
2025
Q1
$1.21M Sell
33,121
-4,904
-13% -$169K ﹤0.01% 2990
2024
Q4
$1.17M Buy
38,025
+21,054
+124% +$700K ﹤0.01% 3278
2024
Q3
$639K Buy
16,971
+12,484
+278% +$481K ﹤0.01% 3623
2024
Q2
$178K Sell
4,487
-7,173
-62% -$232K ﹤0.01% 3635
2024
Q1
$392K Sell
11,660
-8,670
-43% -$291K ﹤0.01% 3736
2023
Q4
$677K Buy
20,330
+15,680
+337% +$506K ﹤0.01% 3696
2023
Q3
$146K Sell
4,650
-1,597
-26% -$50.2K ﹤0.01% 3431
2023
Q2
$198K Sell
6,247
-3,065
-33% -$99.1K ﹤0.01% 3244
2023
Q1
$308K Buy
9,312
+4,368
+88% +$143K ﹤0.01% 3563
2022
Q4
$159K Buy
4,944
+4,164
+534% +$142K ﹤0.01% 3973
2022
Q3
$28K Buy
780
+171
+28% +$7.1K ﹤0.01% 3954
2022
Q2
$25K Sell
609
-1,335
-69% -$64.8K ﹤0.01% 4303
2022
Q1
$112K Buy
+1,944
New +$106K ﹤0.01% 3726
2019
Q3
Sell
-6,052
Closed -$284K 6692
2019
Q2
$284K Buy
6,052
+2,793
+86% +$118K ﹤0.01% 4802
2019
Q1
$114K Buy
3,259
+2,987
+1,098% +$117K ﹤0.01% 5258
2018
Q4
$10K Sell
272
-3,547
-93% -$139K ﹤0.01% 6158
2018
Q3
$130K Buy
3,819
+2,882
+308% +$84.3K ﹤0.01% 5332
2018
Q2
$23K Sell
937
-1,278
-58% -$35.6K ﹤0.01% 6095
2018
Q1
$66K Buy
2,215
+678
+44% +$22.7K ﹤0.01% 5672
2017
Q4
$49K Buy
1,537
+1,318
+602% +$42.4K ﹤0.01% 5769
2017
Q3
$7K Sell
219
-25
-10% -$684 ﹤0.01% 6268
2017
Q2
$6K Buy
244
+72
+42% +$1.67K ﹤0.01% 6177
2017
Q1
$4K Sell
172
-231
-57% -$5.22K ﹤0.01% 6315
2016
Q4
$9K Buy
403
+163
+68% +$3.93K ﹤0.01% 5924
2016
Q3
$6K Sell
240
-257
-52% -$5.74K ﹤0.01% 5941
2016
Q2
$11K Buy
+497
New +$15.7K ﹤0.01% 5492
2015
Q4
Sell
-68
Closed -$2K 5976
2015
Q3
$2K Sell
68
-180
-73% -$5.89K ﹤0.01% 6298
2015
Q2
$10K Buy
+248
New +$11.7K ﹤0.01% 6071

Other funds holding ATEX

Barclays's ATEX Position: Q1 2026 in Review

Barclays reduced its Anterix (ATEX) stake by 89% in Q1 2026, selling an estimated $526K and leaving 2,160 shares worth $82.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4106.

Barclays first reported a position in ATEX in Q2 2015 and has held it in 32 quarters since. The position peaked at $1.21M in Q1 2025. 132 funds tracked by Wall St. Rank hold ATEX as of Q1 2026.

  • Barclays held 2,160 shares of Anterix worth $82.5K as of Q1 2026.
  • Barclays sold 16,629 Anterix shares in Q1 2026, an estimated $526K.
  • Anterix made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4106 holding.
  • Barclays first reported a position in Anterix in Q2 2015 and has held it in 32 quarters since.
  • Barclays's Anterix position peaked at $1.21M in Q1 2025.
  • 132 funds tracked by Wall St. Rank held Anterix as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.